Cellular Biomedicine Lung Cancer IND Application Approved
The FDA has approved Cellular Biomedicine’s Investigational New Drug (IND) application for its tumor infiltrating lymphocyte (TIL) drug candidate C-TIL051 for late-stage non-small cell lung cancer patients who have relapsed or had drug resistance to other therapies.
The investigational drug has shown encouraging safety and efficacy results in preclinical studies and will now advance to early stage trials, the company said.
Cellular Biomedicine said it will begin manufacturing the drug in clinical batches in anticipation of the trials.
About Cellular Biomedicine Group, Inc.
Cellular Biomedicine Group, Inc. operates as a biopharmaceutical company. Cellular Biomedicine Group, Inc, a wholly-owned subsidiary of CBMG Holdings, develops proprietary cell therapies for the treatment of cancer and degenerative diseases. We conduct immuno-oncology and stem cell clinical trials in China using products from our integrated GMP laboratory. Our GMP facilities in China, consisting of twelve independent cell production lines, are designed and managed according to both China and U.S. GMP standards. Headquarters location: Shanghai, China. Founded: 2001.
November 1, 2022
